EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma

J Mullol, V Backer, J Constantinidis, I Eguiluz-Gracia, A L Moure, R Cuervo-Pinto, L Zhang, P Shah, W Kerr, P Hellings

Rhinology Journal · 2024

DOI: 10.4193/rhin24.337 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Rhinology Journal, 2024. Verfasst von J Mullol und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Rhinitis, Nasal Polyps. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic rhinosinusitis with nasal polyps (CRSwNP) often co-exists with asthma and non-steroidal anti-inflammatory drug- exacerbated respiratory disease (N-ERD), creating a more severe phenotype and an additional burden compared with CRSwNP disease alone (1-3). The relationship between these diseases in terms of shared immunological disbalance has been coined in the literature as ‘global airway disease’ or ‘unified airway disease’ and requires integrated treatment strategies (4-6). Our post hoc analysis of the Phase III randomised, double-blind, placebo-controlled, multicentre SYNAPSE study (GSK ID: 205687; NCT03085797 (7)) assessed the efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, in simultaneously improving both CRSwNP and asthma outcomes versus placebo. By utilising a combined measure that accounts for quality of life, sinonasal symptoms and asthma control, we aimed to validate the potential of mepolizumab as an effective therapeutic option for global airway disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaRhinitisNasal PolypsSinusitisHumansDouble-Blind MethodQuality of LifeChronic DiseaseMaleFemaleMiddle AgedAdultTreatment OutcomeInterleukin-5

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedInterleukin-5

Autor:innen und Institutionen

  • Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, IDIBAPS, CIBERES, Barcelona, Catalonia, Spain.
  • Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.
  • Department of ORL, AHEPA University Hospital, Thessaloniki, Greece.
  • Allergy Unit, Hospital Regional Universitario de Malaga, Allergy group, IBIMA-Plataforma BIONAND. RICORS Inflammatory Diseases. Malaga, Spain.
  • Specialty Care Unit, Medical Affairs, GSK, Madrid, Spain.
  • Respiratory Biostatistics, GSK, Warren, NJ, USA.

Zitieren

APA

Mullol, J., Backer, V., Constantinidis, J., Eguiluz-Gracia, I., Moure, A. L., Cuervo-Pinto, R., Zhang, L., Shah, P., Kerr, W., & Hellings, P. (2024). Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma. Rhinology Journal. https://doi.org/10.4193/rhin24.337

Vancouver

Mullol J, Backer V, Constantinidis J, Eguiluz-Gracia I, Moure AL, Cuervo-Pinto R, et al. Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma. Rhinology Journal. 2024. doi:10.4193/rhin24.337

BibTeX
@article{Mullol2024,
  author = {Mullol, J and Backer, V and Constantinidis, J and Eguiluz-Gracia, I and Moure, A L and Cuervo-Pinto, R and Zhang, L and Shah, P and Kerr, W and Hellings, P},
  title = {Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma},
  journal = {Rhinology Journal},
  year = {2024},
  doi = {10.4193/rhin24.337}
}
Kostenlos starten →